Investors
Information Disclosure
-
FINAL DIVIDEND FOR 20252026.03.26
-
CHANGE OF STOCK SHORT NAME IN ENGLISH AND COMPANY WEBSITE2026.03.26
-
VOLUNTARY ANNOUNCEMENT - UPGRADE TO AA IN MSCI ESG RATINGS2026.03.23
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TRD221 "COMPLEMENT PROTEIN MODULATOR" APPROVED BY THE NMPA2026.03.17
-
NOTIFICATION OF BOARD MEETING2026.03.16
-
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III CLINICAL STUDY OF TQB3454 "IDH1 INHIBITOR" FOR BILIARY TRACT CANCER2026.03.12
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQB3205 “PAN-KRAS INHIBITOR” APPROVED BY THE NMPA2026.03.11
-
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR ROVADICITINIB WITH SANOFI2026.03.04